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Objectives The evaluation of the risk of recurring heart failure events (HFEs) was a pre-specified substudy of MADIT-CRT
(Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy).
Background There are limited data regarding the effect of cardiac resynchronization therapy with a defibrillator (CRT-D) on
the occurrence of recurring heart failure episodes after a first post-implantation HFE.
Methods Data with regard to recurring HFEs were prospectively collected for all 1,820 MADIT-CRT participants. The CRT-D
versus defibrillator-only risk for nonfatal first- and subsequent-HFEs was assessed by Cox proportional hazards
and Andersen-Gill proportional intensity regression modeling, respectively, in efficacy analyses recognizing active
device-type during follow-up.
Results Multivariate analysis showed that CRT-D was associated with a significant reduction in the risk of a first HFE
(hazard ratio [HR]: 0.54, 95% confidence interval [CI]: 0.44 to 0.67, p  0.001) and with a similar magnitude of
reduction in the risk of HFEs subsequent to a first post-enrollment event (HR: 0.62, 95% CI: 0.45 to 0.85, p 
0.003). The benefit of CRT-D for the prevention of first and subsequent HFEs was pronounced among patients
with left bundle branch block (HR: 0.38, 95% CI: 0.29 to 0.49, p  0.001; and HR: 0.50, 95% CI: 0.33 to 0.76,
p  0.001, respectively) and nonsignificant in non-left bundle branch block patients (HR: 1.12, 95% CI: 0.77 to
1.64, p  0.55; and HR: 0.99, 95% CI: 0.58 to 1.69, p  0.96, respectively; p values for interaction: p  0.001
and p  0.06, respectively). The occurrences of first and second HFEs were associated with 7- and nearly 19-fold
respective increases in the risk of subsequent mortality.
Conclusions In the MADIT-CRT trial, the benefit of cardiac resynchronization therapy for the reduction in recurring HFEs was
maintained after the occurrence of a first post-enrollment event. The occurrence of HFEs greatly increased the
risk of death. (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy;
NCT00180271) (J Am Coll Cardiol 2011;58:729–37) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.024Heart failure (HF) is an increasing worldwide health prob-
lem and is responsible for an increasing health care burden
in the United States (1). It accounted for more than 1
million hospital discharges in 2006 and was associated with
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accepted April 12, 2011.an overall annual cost of $39.2 billion in 2010 (1). Despite
the success of pharmacological therapy, the rate of repeat
hospital stays for HF has not declined during the past
decade (1,2). During the past 10 years, randomized cardiac
resynchronization therapy (CRT) trials have consistently
shown that treatment with CRT is associated with a
See page 738
significant reduction in the risk of morbidity and mortality
among patients with ischemic or nonischemic cardiomyop-
athy, advanced HF symptoms, and QRS 120 ms (3–10).
Recently, MADIT-CRT (Multicenter Automatic Defibril-
lator Implantation Trial with Cardiac Resynchronization
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and showed a significant 34% re-
duction in risk of the combined
endpoint of a first heart failure
event (HFE) or death with car-
diac resynchronization therapy-
defibrillator (CRT-D) as com-
pared with defibrillator-only ther-
apy in patients with milder HF
symptoms (11). Similar to the
MADIT-CRT trial, prior clinical
trials of CRT have been limited
mainly to an assessment of the
combined endpoint of a first HFE
or death (10–13). Thus, it re-
mains unknown whether the ben-
efit of CRT is maintained after
the occurrence of a first post-
implantation HFE. Evaluation
of recurring HFEs in clinical trials has important clinical,
quality of life, and cost-effectiveness considerations that
cannot be derived from an evaluation of the risk associated
with a first event endpoint. Accordingly, the assessment of
the benefit of CRT-D for the prevention of recurring HFEs
was a pre-specified substudy of the MADIT-CRT trial.
Methods
Study population. The design and primary results of the
MADIT-CRT trial have been recently published (11).
Briefly, the MADIT-CRT trial was designed to determine
whether CRT-D would reduce the risk of death or nonfatal
HFEs in patients with mild cardiac symptoms, a reduced
ejection fraction, and wide QRS complex, when compared
with implantable cardioverter-defibrillator (ICD) therapy.
A total of 1,820 patients were enrolled at 110 hospital
centers in North America and Europe and randomly as-
signed in a 3:2 ratio to receive either CRT-D or ICD.
Patients of either sex who were at least 21 years of age were
enrolled in the study if they had ischemic cardiomyopathy
(New York Heart Association [NYHA] functional class I or
II) or nonischemic cardiomyopathy (NYHA functional class
II only), sinus rhythm, an ejection fraction 0.30, and
prolonged intraventricular conduction with a QRS duration
130 ms. All eligible subjects met the guideline indication
for ICD therapy (12). Patients were excluded from enroll-
ment for a variety of reasons as previously reported (11).
The present study comprises all 1,820 patients enrolled in
the MADIT-CRT trial.
The protocol was approved by the institutional review
board at each participating organization, and each patient
provided written informed consent before enrollment.
Data acquisition and follow-up. The MADIT-CRT trial
was carried out from December 22, 2004, through June 22,
2009. After the study was stopped on the recommendation
Abbreviations
and Acronyms
CI  confidence interval
CRT  cardiac
resynchronization therapy
CRT-D  cardiac
resynchronization
therapy-defibrillator
HFE  heart failure event
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
ITT  intention to treat
LBBB  left bundle branch
block
NYHA  New York Heart
Associationof the data and safety monitoring board, complete datacollection and adjudication of HFE and mortality endpoints
was continued throughout 2009. Thus, the present study
provides extended follow-up data for all MADIT-CRT
participants through December 31, 2009. The incremental
data provided during the post-trial period, representing a
15% increase in follow-up times, are summarized in Online
Table 1.
Data regarding cross-overs between the allocated treat-
ment arms were recorded for all study participants through-
out follow-up and are presented in Online Table 2. Among
the 731 patients randomized to ICD-only therapy, 596
(82%) were treated with an ICD throughout the follow-up
period; and among the 1,089 study participants who were
allocated to CRT-D therapy, 959 (88%) were treated with
the same device throughout follow-up. Notably, among the
186 patients assigned to ICD-only therapy who had a first
HFE, 68 (37%) crossed over to the CRT-D arm after the
occurrence of a first HFE (in 4.8 months, on average),
whereas among patients allocated to CRT-D therapy, a
change in treatment arm occurred most frequently before
the occurrence of a first HFE (8% of all patients allocated to
CRT-D therapy crossed over to ICD-only therapy before
the occurrence of a first HFE, as compared with only 1%
after a first HFE).
Study design and endpoints. The MADIT-CRT protocol
did not call for evaluating a potential differential effect of
CRT-D with baseline QRS morphology. However, after
publication of the primary report (11), analyses were done
comparing left bundle branch block (LBBB) patients—
comprising 70% of the study patients—with non-LBBB
patients (30%; including 13% with right bundle branch
block and 17% with an intraventricular conduction defect),
revealing evidence that the CRT-D benefit of reducing risk
of the primary endpoint seemed to be largely or even
entirely in the LBBB subgroup (13). Consequently, on
September 16, 2010, the Food and Drug Administration
extended approval of the use of the CRT-D only in the
LBBB subgroup of the MADIT-CRT–defined population
(14). Each analysis in the present study allowed for possible
differential effects by QRS morphology—specifically, LBBB
or non-LBBB at baseline—consistent with this finding and
recommendation.
The primary endpoint of the present study was the
occurrence of recurring HFEs after a first post-enrollment
HFE, hereafter referred to as subsequent HFEs. The effects
of first and subsequent HFEs on the risk of subsequent
all-cause mortality were also assessed. The diagnosis of an
HFE, made by physicians aware of the implanted devices,
required signs and symptoms consistent with congestive HF
that was responsive to intravenous decongestive therapy on
an outpatient basis or an augmented decongestive regimen
with oral or parenteral medications during an in-hospital
stay. Adjudication of the endpoints was carried out by an
independent HFE committee blinded to device implanta-
tion information. Data for patients who experienced subse-
quent HFEs within 2 weeks of a prior HFE were further
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August 9, 2011:729–37 Prevention of Recurrent HF With CRT-Dreviewed to distinguish ongoing HFEs (defined as events
that occurred within 2 weeks of a prior HFE in which the
patient continued to experience HF symptoms at hospital
discharge or after outpatient intravenous diuretic therapy)
from new HFEs (defined as events occurring at any time
after a prior HFE in which the patient was considered to be
fully stabilized at hospital discharge or after outpatient
intravenous therapy). Forty-seven subsequent HFEs (15%
in the ICD-only arm and 14% in the CRT-D arm) were
identified with these definitions as ongoing HFEs and
therefore were combined with the prior event. In the
analyses of all-cause mortality, 14 patients (8 in the ICD-
only arm and 6 in the CRT-D arm) who died within 2
weeks of device deactivation due to terminal HF were
categorized as being allocated at the time of death to the
device that was employed before deactivation.
Statistical methods. FIRST AND SUBSEQUENT HFEs. Be-
ause risk of HFEs increased measurably after a first HFE
due to identification of patients with high on-going risk
nd/or changes due to occurrence of the event), the risk for
ubsequent HFEs (among patients who experienced a first
FE) was analyzed separately from the first HFE endpoint.
o further distinctions in risk for second, third, or addi-
ional HFEs were made, because there was lesser evidence
f distinctions among them and data become sparse with
ncreasing HFE count. Deaths subsequent to a first HFE
ere also analyzed.
EFFICACY AND INTENTION-TO-TREAT ANALYSES. Because
any patients with an ICD-only had CRT capability added
o their devices after experiencing a first HFE, intention-
o-treat (ITT) analyses of events subsequent to a first HFE
ave limited interpretability. Therefore, primary analyses in
his study were carried out on an efficacy basis, comparing
isks of events occurring while specific devices were active.
fficacy analyses were further categorized as full (incorpo-
ating complete follow-up data for each patient after cross-
ver between devices) and modified (with follow-up cen-
ored upon the first occurrence of cross-over between
evice-types or transition to no device). Daily records were
ept for each patient as to whether an ICD-only was active,
CRT-D was active, or no device was active (e.g., before any
mplantation, during temporary device inactivation, or after
evice explantation). Follow-up for each patient was allo-
ated into these 3 categories, with risk for a first HFE
valuated from the time of enrollment and risk for subse-
uent HFEs evaluated from the time of the first HFE (for
more detailed explanation of the follow-up methodology
hat was employed in the efficacy analyses, see Fig. 1).
Secondary analyses were carried out on an ITT basis,
comparing devices by original treatment allocation, regard-
less of cross-over during follow-up.
COVARIATE-ADJUSTED ANALYSES OF RISK. For first HFEs,
Cox proportional hazards regression modeling was used,
tracking active-device types as time-dependent covariates;
for subsequent HFEs, Andersen-Gill proportional-intensity oregression modeling was similarly used (15) (this separation
of risk of a first event and risk of later events is similar to
what is done in a modified conditional Prentice, Williams,
and Peterson analysis [16] but allows for different contri-
butions from covariates to the respective risk analyses). For
subsequent HFEs, time of first HFE was included as a
covariate. All models included, besides device type, baseline
LBBB status and its interaction with device type. Twenty-
seven baseline covariates with 5% missing data were
selected as potential risk factors (brain natriuretic peptide, a
known risk factor for HFEs, was the only covariate that was
omitted due to substantial missing data). Missing baseline
values for covariates were imputed by linear or logistic
regression (so as not to omit these patients from further
analyses), and then all variables were dichotomized at
pre-specified cutpoints. The list was reduced with best-
subsets regression methods, separately for first HFEs and
for subsequent HFEs, and the union of the 2 resulting sets
of covariates was used as a common set of risk factors in
regression analyses of both first and subsequent HFEs.
Interaction terms between device types and each selected
covariate were later considered, including interaction by sex
and by QRS, because these interactions had been identified
and reported earlier (11), before consideration of LBBB
status in regression modeling. Because follow-up with no
active device was limited (1.4% of the total), and with few
events occurring during it (14 HFEs [2.3% of total HFEs]
and 20 deaths [12.5%]), no evaluations of relative risk of
ICD-only to no active device are reported.
CRUDE EVENT RATES. Counts of events/100 patient-years
f risk were computed, both for first and for subsequent
FEs. These are crude composite descriptive measures of
isk, ignoring variation in risk across patients and ignoring
he competing risk of mortality; no statistical tests were
ndertaken.
SURVIVAL CURVES. When no time-dependent factors—
such as active device type—were employed, Kaplan-Meier
survival curves for the first of HFE or death (but not for first
HFE alone due to the competing risk of mortality) were
constructed but limited to time from implantation or from
first HFE, with censoring at any device change or explan-
tation. Kaplan-Meier curves for death were constructed,
from time of enrollment, and for the subset of patients with
a first HFE from the time of that HFE and for the further
subset with a second HFE from the time of that HFE.
SOFTWARE. The statistical software used for the analyses
as SAS (version 9.2, SAS, Cary, North Carolina). A
-sided p value 0.05 was used for declaring statistical
ignificance.
esults
he baseline clinical, echocardiographic, and medication
haracteristics of MADIT-CRT patients appear in Table 1
f the primary publication (11). Table 1 herein includes
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the regression analyses, with counts of those experiencing
0, 1, and 2 HFEs during follow-up. Patients who
experienced HF during follow-up displayed a higher
frequency of baseline clinical risk factors as compared
with those who did not experience HFEs, including older
age, diabetes mellitus, renal dysfunction, advanced HF
class 3 months before enrollment, shorter distance
walked in a 6-min test, increased frequency of history of
atrial fibrillation before enrollment, and higher levels of
brain natriuretic peptide. In addition, patients who ex-
perienced multiple HFEs displayed more advanced base-
line echocardiographic parameters as compared with
those who experienced single or no events, including
significantly higher left ventricular and atrial volumes and
a lower ejection fraction (Table 1).
Effect of therapy on the risk for first and subsequent
HFEs. Of the 1,820 study patients, 347 (19%) had a
first HFE during an average follow-up of 2.6 years. After
the occurrence of a first HFE, the rate of subsequent
HFEs was substantially increased. Thus, of the 347
Figure 1 Schematic Presentation of Efficacy Analysis: Follow-U
Schematic diagram showing attribution of follow-up time to type of device active a
This is in contrast to intention-to-treat (ITT) analyses, which categorize by randomi
follow-up time, whereas ITT analyses categorize patients. Patient #1: soon after e
successfully implanted; it remained active until the study ended (December 31, 20
attributed to an active CRT-D device. Patient #2: After a short delay, a CRT-D devic
repositioning due to diaphragmatic irritation (at which follow-up was censored in th
later a second HFE occurred (considered to be the first event for the analysis of s
part of the follow-up for first HFE (and for death) is attributed to each device-type;
Patient #3: soon after enrollment, an implantable cardioverter-defibrillator (ICD)-on
soon thereafter CRT capability was added (at which time follow-up was censored i
were considered to be the initial events on CRT-D in the analysis for subsequent e
short while later. Follow-up for first HFE is attributed to “no active device” and to I
attributed to each of the 3 device-type categories. For analysis of subsequent eve
parts of that for Patient #3 are attributed to each of the 3 device types.patients who experienced a first HFE, 142 (41%) hadbetween 1 and 9 additional subsequent HFEs during an
average of 1.5 years after the first event (Online Tables 3
and 4). Consistent with these findings, the cumulative
probability of HF and death was substantially higher
immediately after the occurrence of a first HFE, regard-
less of the type of active device-type at the time of the
event (Figs. 2A to 2C).
Full efficacy analysis (i.e., incorporating complete active
device follow-up data) showed that in the total study
population active treatment with CRT-D was associated
with a significant 46% (p  0.001) reduction in the risk of
a first HFE, as compared with active ICD-only therapy
(hazard ratio [HR]: 0.54, 95% confidence interval [CI]:
0.44 to 0.67, p  0.001) (Table 2) and with a similar
magnitude of risk reduction after the occurrence of a first
event (38% risk reduction [i.e., HR: 0.62, 95% CI: 0.45 to
0.85, p  0.003]) (Table 2). Notably, despite a similar
magnitude of risk reduction associated with CRT-D ther-
apy before and subsequent to a first HFE, the absolute
reduction in event rates (per 100 patient-years) with
CRT-D therapy was more pronounced after the occurrence
Active Device
me, used in efficacy analyses presented in Tables 2 and 3 and Figures 2 and 3.
atment assignment (presented in Table 2). Hence, efficacy analyses categorize
nt, a cardiac resynchronization therapy with a defibrillator (CRT-D) device was
ll follow-up was for a first heart failure event (HFE) and for death, most of it
implanted; it remained active for some while, except for a few days when lead
ified efficacy analysis). A first HFE occurred while it was active, and some while
ent HFEs); the study terminated a short while later. In the full efficacy analysis,
up for subsequent HFEs (and subsequent death) is attributed entirely to CRT-D.
inserted and remained active for some while. A first HFE was experienced, and
odified efficacy analysis). While the CRT-D was active, 2 HFEs occurred (which
. Shortly after the last one, the device was explanted, with death occurring a
y; part of the follow-up for subsequent events in the full efficacy analysis is
tient #1 is omitted; follow-up for Patient #2 is attributed to CRT-D, whereasp by
t the ti
zed tre
nrollme
09). A
e was
e mod
ubsequ
follow-
ly was
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nts, Paof a first HFE (Fig. 3).
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that the benefit of CRT-D therapy for the prevention of
both first and subsequent HFEs was pronounced among
patients who had LBBB at enrollment (first: HR: 0.38, 95%
CI: 0.29 to 0.49, p 0.001; and subsequent: HR: 0.50, 95%
CI: 0.33 to 0.76, p  0.001) and nonexistent among
on-LBBB patients (first: HR: 1.12, 95% CI: 0.77 to 1.64,
Baseline Clinical Characteristics, by theNumber of HFEs Experienced During Follow-UpTable 1 Ba eline Cli ical Charac eristics, by theNumber of HFEs Experienced During Follow-Up
Characteristics
Number of HFEs
p Value*
No HFE
(n  1,497)
1 HFE
(n  197)
>2 HFEs
(n  126)
Randomized to ICD-only 37 54 53 0.001
Randomized to CRT-D 63 46 47 0.001
Age 70 yrs 33 46 42 0.001
Female 25 25 18 0.20
Black race 7 12 8 0.09
Current cigarette smoking 12 10 19 0.06
Prior hospitalization for
heart disease
45 54 58 0.001
Walked 400 m in 6 min 36 24 27 0.001
Ischemic heart disease 53 62 64 0.003
NYHA functional class II† 85 86 84 0.80
NYHA functional class III
3 months before
enrollment
10 10 19 0.002
Hypertension 63 69 65 0.21
Diabetes mellitus 29 39 39 0.001
Past atrial fibrillation 10 16 19 0.002
Past CABG 28 34 36 0.04
LBBB 71 69 65 0.29
QRS duration 150 ms 66 62 56 0.08
Systolic BP 120 mm Hg 59 57 52 0.27
Diastolic BP 80 mm Hg 28 25 22 0.21
GFR 60 30 44 48 0.001
BMI 30 kg/m2 36 38 33 0.60
BUN 25 mg/dl 23 30 34 0.004
SCr 1.4 mg/dl 20 26 36 0.001
BNP level 150‡ 23 36 44 0.001
Baseline echocardiographic
parameters§
LVEF 25% 10 15 21 0.001
LVESV 90 ml/m2 36 39 50 0.003
LAV 50 ml/m2 29 41 59 0.001
Baseline medications
Diuretics 65 77 86 0.001
All entries are percentages with the characteristic, among those who experienced the indicated
number of heart failure events (HFEs) during follow-up. The first 2 rows apply only to ITT analyses.
The other characteristics included are limited to those considered as potential risk factors for HFEs,
for later regression analyses; a fuller list appears in Table 1 of Moss et al. (11) (U.S. vs. non-U.S., and
mall center vs. large center, identifications were also considered in analyses but are omitted here).
The statistical significance of the difference among covariates in the 3 HFE subgroups was
ssessed with a chi-square test comparing 3 percentages. †The highest New York Heart Associa-
ion (NYHA) functional class during the 3 months before enrollment. ‡Brain natriuretic peptide
BNP) information was missing for 623 patients (34%) and was omitted from further analyses. §All
chocardiographic parameters are based on core laboratory data; volume measures were indexed
o body mass index (BMI).
BP  blood pressure; BUN  blood urea nitrogen; CABG  coronary artery bypass graft surgery;
CRT-D cardiac resynchronization therapy-defibrillator; EF ejection fraction; ICD implantable
cardioverter-defibrillator; LVEF  left ventricular ejection fraction; LVEDV  left ventricular end
diastolic volume; LVESV  left ventricular end systolic volume; LAV  left atrial volume; SCr 
serum creatinine. 0.55; and subsequent: HR: 0.99, 95% CI: 0.58 to 1.69, ap  0.96; p values for interaction: p 0.001 and p  0.06,
espectively) (Table 2). All differences between HRs for first
Figure 2 Risk of HF or Death After Device Implantation
Cumulative probability of the first HFE or death after implantation and, in the
subset of patients with a first HFE, after an additional HFE or death, among all
study patients (A) and among patients with (B) and without (C) left bundle
branch block (LBBB) on the baseline echocardiogram. Survival curves were lim-
ited to time from implantation or from first HFE, with censoring at any device
change or explantation. The p values for the comparison between the 2 treat-
ment arms before and after a first HFE are: (A) 0.001 and 0.32, respectively;
(B) 0.001 and 0.12, respectively; and (C) 0.30 and 0.94, respectively.
Abbreviations as in Figure 1.nd subsequent HFEs were nonsignificant, and no other
-D with
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the LBBB/non-LBBB differences were allowed for in the
regression models. Specifically, with LBBB status in the
analyses, the earlier report (11) of differential effects of CRT-D
therapy relative to ICD-only by QRS width was no longer
evident, and that by sex was greatly diminished (p value for a
differential treatment effect by sex for the endpoints of first and
subsequent HFEs; p  0.07 and p  0.73, respectively).
Consistent with these findings, active treatment with
CRT-D was associated with approximately one-half the
rate for both first and subsequent HFEs, as compared with
Multivariate Analysis: Relative Risk of Time-Dependent CRT-D VersTable 2 Multivariate Analysis: Relative Risk of Time-Dependen
All Patients
Endpoint HR (95% CI) p Value HR (95
Full efficacy analysis†
First HFE 0.54 (0.44–0.67) 0.001 0.38 (0.2
Subsequent HFEs 0.62 (0.45–0.85) 0.003 0.50 (0.3
Modified efficacy analysis*
First HFE 0.52 (0.42–0.65) 0.001 0.36 (0.2
Subsequent HFEs 0.62 (0.44–0.87) 0.007 0.51 (0.3
ITT analysis‡
First HFE 0.53 (0.43–0.66) 0.001 0.39 (0.3
Subsequent HFEs 0.76 (0.56–1.05) 0.10 0.76 (0.4
The endpoint of a first HFE was assessed in 1,820 patients (337 events) with Cox regression mod
(270 events) with Andersen-Gill regression modeling. All models used a common list of 12 baseli
index50 ml/m2, treatment with diuretics, diabetes mellitus, hospital stay for heart failure at any
age 70 years, QRS 150 ms, history of prior atrial fibrillation, ischemic etiology of cardiomyopa
LBBB and CRT-D as active device; 15 other covariates that were considered but dropped as not con
as a risk factor but dropped as not contributing. No other statistically significant interactions in th
no active device for both full and modified efficacy analyses are omitted here due to limited data. *
follow-up when a first device change occurs; these analyses were based on less follow-up time a
approximately 25% less for analysis of subsequent HFEs) but are not affected by any cross-over ac
with daily records, without censoring on device change. ‡Intention-to-treat analyses compare CRT
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.
Figure 3 Rate of First and Subsequent HFEs by Active Device T
Crude rates for first heart failure events (HFEs) (A) and for subsequent HFEs (B),
out left bundle branch block (LBBB) on the baseline echocardiogram. Event rates/
of active device therapy by the total follow-up time on that therapy and multiplying
competing risk of death. See Online Table 3.ICD-only therapy among patients with LBBB, but had a
less-pronounced effect on the rate of subsequent HFEs
among non-LBBB patients (Fig. 3).
A modified efficacy analysis (Table 2), in which follow-up
during active device therapy was censored at the time of the
first cross-over, yielded results virtually identical to those
obtained from the full efficacy analyses. This analysis was
not affected by any cross-over activity after a first HFE,
further suggesting that the benefit of CRT-D therapy for
the reduction of subsequent HFEs is maintained after the
occurrence of a first HFE.
D-Only Therapy for First and Subsequent HFEs-D Versus ICD-Only Therapy for First and Subsequent HFEs
By QRS Morphology
Patients Non-LBBB Patients
p for Difference*p Value HR (95% CI) p Value
9) 0.001 1.12 (0.77–1.64) 0.55 0.001
6) 0.001 0.99 (0.58–1.69) 0.96 0.06
7) 0.001 1.09 (0.74–1.61) 0.66 0.001
1) 0.004 0.89 (0.49–1.60) 0.69 0.16
1) 0.001 1.01 (0.69–1.48) 0.96 0.001
8) 0.22 0.77 (0.48–1.23) 0.27 0.98
nd the endpoint of subsequent recurring HFEs was assessed in the 337 patients with a first HFE
factors as covariates (listed in order of contributions to the model for first HFE): left atrial volume
fore enrollment, distance walked in a 6-min test of400 m, serum creatinine1.3 mg/dl, LBBB,
NYHA functional class III more than 3 months before enrollment, and also interaction between
g to either analysis are listed in Table 1. For subsequent analyses, time of first HFE was considered
ls for HFEs were identified once LBBB status was included in all models. Results for periods with
d efficacy analyses compare active CRT-D usage relative to ICD-usage after enrollment and censor
er events than the full efficacy analyses (approximately 5% less for analysis of a first HFE, and
ter a first implantation. †Full efficacy analyses compare active CRT-D usage relative to ICD-usage
ICD-only by original device allocation.
ive device-type, in the total study population and among patients with and with-
erson-years were calculated by dividing the number of events during the periods
0. These rates ignore variation across patients in risk and follow-up time and theus ICt CRT
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August 9, 2011:729–37 Prevention of Recurrent HF With CRT-DIntention-to-treat-analysis (i.e., on the basis of original
treatment allocation) showed results similar to those ob-
tained from the efficacy analyses when the endpoint of a first
HFE was assessed (Table 2). However, randomization to
CRT-D therapy was not associated with a statistically
significant reduction in the risk of subsequent HFEs, as
compared with randomization to ICD-only therapy (Table 2),
suggesting that assignment of the relatively large proportion of
ICD-only patients who crossed over to CRT-D therapy after
the occurrence of a first HFE (37%) to the original ICD-only
randomization group attenuated the statistical significance of
the association between active CRT-D therapy and the risk of
subsequent HFEs.
HFEs and the risk of subsequent all-cause mortality.
During follow-up, 160 patients died—of whom 50 were
treated with an ICD at the time of death, 90 with
CRT-D, and 20 had the device explanted/deactivated
before death for a reason that was not known to be related
to terminal HF (Online Table 3). Multivariate Cox
proportional hazards regression modeling showed that
active treatment with CRT-D was not associated with a
significant reduction in the risk of death, as compared
with ICD-only therapy in the total study population
(HR: 0.95, 95% CI: 0.67 to 1.34). However, risk reduc-
tion associated with CRT-D therapy was significantly
greater among patients with LBBB (HR: 0.75, 95% CI:
0.49 to 1.14) than among non-LBBB patients (HR: 1.65,
95% CI: 0.87 to 3.13; p value for treatment  LBBB
interaction: p  0.03).
The occurrences of first and second HFEs were the
most powerful predictors of mortality in the MADIT-
CRT population. Among all study patients, the occur-
rence of a first HFE was associated with a 7-fold (p 
0.001) increase in the risk of subsequent all-cause mor-
tality; and the development of a second HFE was
associated with a 2.6-fold (p  0.001) further risk
increase, resulting in a nearly 19-fold increase in the risk
of death as compared with mortality risk before the occur-
rence of a first HFE (Table 3). The pronounced effects of
both first and second HFEs on the risk of subsequent
mortality were evident among patients treated with either
active device-type (Table 3). Results regarding the effect of
Multivariate Analysis: Relative Risk of Time-Dependent HFEs for thOccurrence of Al -Cause Mortality in All Patients and When TrackeTable 3 Multivariate Analysis: Relat ve Risk of Time-DependenOccurrence of All-Cause Mortality in All Patients and W
All Patients
Risk Factor HR (95% CI) p Value HR (95%
First HFE vs. no HFE 7.24 (5.85–10.8) 0.001 7.04 (3.37
Second HFE vs. no HFE 18.7 (12.3–28.5) 0.001 30.3 (15.8
Efficacy analyses compare active CRT-D usage relative to ICD-usage with daily records; results for
was assessed with Cox regression modeling with time-dependent risk factors for occurrence of fi
contributions, with HRs from 1.89 down to 1.58, were distance walked in a 6-min test of400 m,
and serum creatinine 1.3 mg/dl.
Abbreviations as in Tables 1 and 2.a first and second HFE on the risk of death were consistentwhen device-type was assessed on an ITT-basis (Online
Table 5). Additional factors in the multivariate analysis had
a less pronounced effect on the risk of all-cause mortality,
including distance walked in a 6-min test of 400 m (HR:
1.89, 95% CI: 1.26 to 2.82), NYHA functional class III
more than 3 months before enrollment (HR: 1.80, 95% CI:
1.99 to 2.72), ischemic etiology of cardiomyopathy (HR:
1.64, 95% CI: 1.13 to 2.37), and serum creatinine 1.4
mg/dl (HR: 1.58, 95% CI: 1.14 to 2.20).
Consistent with the findings from the multivariate mod-
els regarding mortality risk associated with the development
of HF, Kaplan-Meier survival analysis showed that the
cumulative probability of all-cause mortality was 5% 2 years
after enrollment among all study patients, 29% 2 years after
the occurrence of a first HFE among those with a first
HFE, and 46% 2 years after the occurrence of a second
HFE among that subgroup (Fig. 4).
Active Devices for the
Tracked by Active Device
By Active Device-Type
Only CRT -D
p for Differencep Value HR (95% CI) p Value
) 0.001 5.86 (3.47–9.88) 0.001 0.69
0.001 17.4 (10.3–29.2) 0.001 0.17
with no active device, having limited data, are omitted here. The endpoint of all-cause mortality
second HFEs. Other covariates were as listed in the footnote to Table 2; those with significant
unctional classIII more than 3 months before enrollment, ischemic etiology of cardiomyopathy,
Figure 4 Probability of Death From Enrollment and After HFEs
Cumulative probability of all-cause mortality among all study patients (with
time 0 starting at implantation), among those who experienced 1 heart fail-
ure event (HFE) during follow-up (with time 0 starting at the occurrence of a
first HFE) and those who experienced 2 HFEs during follow-up (with time
starting at the occurrence of a second HFE). Data are shown without a statisti-
cal comparison, because the 3 curves are based on successive subsets of a
single group of patients. Patients who never received a device (n  30) are
omitted.ed byt HFE
hen
ICD-
CI)
–14.7
–5.2)
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rst and
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The MADIT-CRT trial showed that CRT-D therapy is
associated with a significant reduction in the risk of a first
HFE or all-cause mortality in asymptomatic or mildly
symptomatic patients with left ventricular dysfunction (11).
The present study is the first to assess the benefit of CRT-D
for the prevention of recurring HFEs in a clinical trial and,
therefore, extends the observations of the original report.
We have shown that treatment with CRT-D was associated
with a significant reduction in the risk of recurring episodes
of HF among study patients even after the occurrence of a
first post-enrollment HFE. Recurring HF was shown to be
the most powerful predictor of subsequent mortality in the
MADIT-CRT population, further stressing the important
long-term implications of identifying measures for the
prevention of repeated HF episodes.
Heart failure is a common chronic disease marked by
frequent exacerbations often resulting in hospital stay and
death (1). Readmission for HF occurs in 20% of patients
within 30 days of discharge in those over age 65 years, and
this might exceed 50% at 6 months (17,18). Despite current
HF therapies, recent data (2) suggest an increase in the rate
of repeat hospital stays after HF. The high rate of repeat
hospital stays is a major contributor to the estimated $39.2
billion in cost of HF care in the United States for 2010 (1).
Therefore, the identification of therapies that reduce the
risk of recurring HF has incremental health, economic, and
quality-of-life implications that extend beyond the tradi-
tional first event endpoint. The present study shows a very
high rate of repeated HF episodes (41%) after the occur-
rence of a first post-enrollment HFE even in the MADIT-
CRT population, which comprised asymptomatic or mildly
symptomatic patients. Accordingly, the absolute reduction
in the rate of recurring events with CRT-D therapy in the
trial was substantially higher than the corresponding reduc-
tion in the rate of first events (Fig. 3), even though the
magnitude of relative risk reduction associated with the
device before and after the occurrence of a first HFE was
similar.
It should also be noted that in the MADIT-II (Multi-
center Automatic Defibrillator Implantation Trial) the sig-
nificant survival benefit of the ICD was shown to be
associated with a significant increase in the risk of recurrent
HFEs (19). Furthermore, we have recently shown in an
extended 8-year follow-up of the MADIT-II population
that the long-term survival benefit of the ICD is attenuated
among patients who develop HF after device implantation
(20). These data further stress the importance of timely
intervention with CRT for the reduction in the risk of
recurrent HFEs and death in appropriately selected candi-
dates for primary prevention with an ICD.
Response to CRT is usually assessed with a variety of
clinical and echocardiographic measures, which usually
includes the occurrence of a first HFE (2–4,21). Prior
studies suggested that approximately one-third of the pa-tients who receive CRT in clinical trials can be considered
nonresponders to treatment with the device, due to the
occurrence of symptomatic HF after implantation. Cur-
rently, however, there are limited data regarding the subse-
quent outcome of this high-risk patient subset. In the
present study we employed the Andersen-Gill proportional-
intensity regression model to assess the clinical course of
patients enrolled in the MADIT-CRT trial who experi-
enced a first HFE. Findings from this analysis show that
treatment with CRT-D was associated with a significant
38% reduction (50% in LBBB patients) in the risk of
repeated HF episodes subsequent to a first event. Thus, our
data suggest that patients who were considered in some
prior studies as nonresponders (due to the occurrence of a
HFE after CRT implantation) might continue to derive a
pronounced clinical benefit from CRT even after the occur-
rence of a post-implantation HFE. Notably, the time to a
first HFE was not found to be influential in assessing the
risk of subsequent HFEs, suggesting that reduction of
subsequent of HFEs with CRT-D is maintained regardless
of when the first post-implantation HFE occurs.
Treatment with CRT-D was associated with a pro-
nounced reduction in the risk of both first and subsequent
HFEs among patients with LBBB but had no detectable
effect on either of the 2 endpoints among non-LBBB
patients. No other statistically significant interactions, in-
cluding gender and QRS width, were identified once the
LBBB/non-LBBB differences were allowed for in the re-
gression models. The pronounced effect of CRT-D therapy
among women noted in the earlier report (11) might be
attributed to the fact that 87% of the women in the trial had
LBBB at enrollment. These findings are consistent with the
recent Food and Drug Administration approval of the use of
the CRT-D only in the LBBB subgroup of the MADIT-
CRT–defined population (14).
The present study shows that first and second post-
enrollment HF episodes were associated with 7- and nearly
19-fold respective increases in the risk of subsequent all-
cause mortality in the MADIT-CRT population. Further-
more, Kaplan-Meier survival analysis showed the cumula-
tive rate of all-cause mortality after the occurrence of a
second HFE was nearly 50% within 2 years. Thus, although
CRT-D therapy was not associated with a significant
reduction in the risk of all-cause mortality during the trial
(11), it is likely that the reduction in the risk for repeated
HF episodes with CRT will translate into a survival benefit
during longer-term follow-up.
Study limitations. We designed the present study primar-
ily as an efficacy analysis in which the outcome of study
patients was assessed during active device therapy rather
than by the original treatment allocation, due to the rela-
tively large proportion of ICD-allocated patients who ex-
perienced HFE and subsequently crossed over to the
CRT-D arm (37%). Potential imbalances were addressed by
using covariate adjustments rather than depending on ran-
domization and stratification.
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August 9, 2011:729–37 Prevention of Recurrent HF With CRT-DAlthough risk seems to further increase after a second
HFE, most analyses treated all subsequent HFEs uniformly,
due to smaller numbers and for simplification in presenta-
tion. A sensitivity analysis substantiated this.
Big differences were uncovered between responses in
LBBB and non-LBBB patients. The primary results were
confirmed by repeating the main analyses within the LBBB
subgroup, thereby avoiding proportional hazards assump-
tions between QRS morphology subgroups.
Conclusions and Clinical Implications
Randomized clinical trials of CRT are generally designed to
evaluate an endpoint that comprises initial clinical events,
even though prevention of recurring episodes with device
therapy has incremental clinical and prognostic implica-
tions. The results of the present MADIT-CRT sub-study
show for the first time that CRT is associated with a
pronounced reduction in the risk of repeated HF episodes.
Furthermore, the present results confirm the prognostic
implications of recurring HFEs in patients with left ven-
tricular dysfunction. These findings should be incorporated
in the risk assessment and management of patients who
receive device therapy for the prevention of HF and sudden
cardiac death and stress the importance of evaluating risk for
recurrent events in clinical trials.
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